#Oncology — FinScans

Release 📈 Stocks — 📊 Neutral

AHN Appoints Dr. Nipun Merchant as Chair of Surgery and Cancer Institute Lead

October 14, 2026 (19 days ago)

Allegheny Health Network taps surgical oncologist Dr. Nipun B. Merchant to lead its Department of Surgery and newly established Cancer Institute, signaling…

🌍 AMERICAS Read More →

Release 📈 Stocks — 📊 Neutral

T-Maximum Pharmaceutical Receives FDA Clearance for Phase 2 MT027 CAR-T Trial

October 12, 2026 (22 days ago)

T-Maximum Pharmaceutical advances its oncology pipeline after receiving FDA clearance to initiate a Phase 2 clinical study for MT027, a B7-H3-targeted allogeneic…

🌍 ASIA Read More →

Release 🌐 Macro — 📊 Neutral

NCCN Expands Global Cancer Treatment Standardization Efforts in 2026

October 8, 2026 (26 days ago)

NCCN targets global clinical standardization through strategic partnerships at the International Gynecologic Cancer Society and Philippine Society of Medical Oncology annual meetings.

🌍 GLOBAL Read More →

News 🌐 Macro — 📊 Neutral

Thyme Therapeutics Launches to Target Oncology Biologics Market

October 8, 2026 (26 days ago)

Thyme Therapeutics enters the oncology market as major biologics face patent cliffs, seeking to address ongoing pricing instability and the rise of…

Alpha-9 Oncology to Present Clinical Data on Targeted Radiotherapeutics

October 8, 2026 (26 days ago)

Alpha-9 Oncology prepares to showcase new clinical findings for its targeted radiotherapeutic pipeline, highlighting advancements in next-generation cancer treatment development.

🌍 AMERICAS Read More →

Release 🌐 Macro — 📊 Neutral

Karmanos Cancer Institute Appoints Dr. Stefan Grant as Associate Director

October 6, 2026 (27 days ago)

Dr. Stefan C. Grant joins the Karmanos Cancer Institute, leveraging three decades of oncology experience to bolster the organization's clinical trial and…

🌍 AMERICAS Read More →

Release 📈 Stocks

AbbVie and Genmab Report Positive Phase 3 Results for Epcoritamab in DLBCL

October 5, 2026 (28 days ago)

AbbVie and Genmab shares gain as the EPCORE DLBCL-2 trial demonstrates superior progression-free survival for frontline lymphoma patients using their bispecific antibody…

ABBV GMAB

🌍 GLOBAL Read More →

Release 📈 Stocks — 📊 Neutral

51% of U.S. Drug Launches Beat Wall Street Revenue Forecasts in 2025

October 5, 2026 (28 days ago)

Trinity Life Sciences reports that 51% of 2025 U.S. drug launches exceeded Wall Street revenue targets, with oncology products leading the sector's…

🌍 AMERICAS Read More →

News 📈 Stocks

AstraZeneca Camizestrant Approval Poised to Drive SERD Market Growth

October 5, 2026 (28 days ago)

AstraZeneca's camizestrant approval acts as a catalyst for the expanding SERD market, with growth driven by demographic shifts and advancements in breast…

AZN

🌍 GLOBAL Read More →

Release 📈 Stocks

Provectus Biopharmaceuticals Reports 95.5% Response Rate in Oral Cancer Trial

October 5, 2026 (28 days ago)

Provectus Biopharmaceuticals shares rally as Phase 2 trial data for PRV111 shows a 95.5% pathologic complete response rate in early-stage oral cancer…

PVCT

🌍 AMERICAS Read More →

Release 📈 Stocks

Eli Lilly Gains FDA Approval for Jaypirca to Treat CLL and SLL Patients

October 2, 2026 (31 days ago)

Eli Lilly expands its oncology footprint as the FDA approves Jaypirca for the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma,…

LLY

🌍 AMERICAS Read More →

Release 📈 Stocks

PhytoHealth CEO Receives Industry Award for PG2 Cancer Fatigue Drug

October 2, 2026 (32 days ago)

PhytoHealth CEO Angel Lee earns industry recognition for the development of PG2, a breakthrough botanical treatment for cancer-related fatigue, bolstering the company's…

4128.TW

🌍 ASIA Read More →